Correction : Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885

The authors wish to make the following corrections to this paper [...]

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain : Large-Scale Epidemiological Study

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery

Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol

Introduction In recent years, multiple studies have aimed to develop and validate portable technological devices capable of monitoring the motor complications of Parkinson's disease patients (Parkinson's Holter). The effectiveness of these monitoring devices for improving clinical control is not known. Methods and analysis This is a single-blind, cluster-randomised controlled clinical trial. Neurologists from Spanish health centres will be randomly assigned to one of three study arms (1:1:1): (a) therapeutic adjustment using information from a Parkinson?s Holter that will be worn by their patients for 7 days, (b) therapeutic adjustment using information from a diary of motor fluctuations that will be completed by their patients for 7 days and (c) therapeutic adjustment using clinical information collected during consultation. It is expected that 162 consecutive patients will be included over a period of 6 months. The primary outcome is the efficiency of the Parkinson?s Holter compared with traditional clinical practice in terms of Off time reduction with respect to the baseline (recorded through a diary of motor fluctuations, which will be completed by all patients). As secondary outcomes, changes in variables related to other motor complications (dyskinesia and freezing of gait), quality of life, autonomy in activities of daily living, adherence to the monitoring system and number of doctor?patient contacts will be analysed. The noninferiority of the Parkinson's Holter against the diary of motor fluctuations in terms of Off time reduction will be studied as the exploratory objective. Ethics and dissemination approval for this study has been obtained from the Hospital Universitari de Bellvitge Ethics Committee. The results of this study will inform the practical utility of the objective information provided by a Parkinson's Holter and, therefore, the convenience of adopting this technology in clinical practice and in future clinical trials. We expect public dissemination of the results in 2022.Funding This work is supported by AbbVie S.L.U, the Instituto de Salud Carlos III [DTS17/00195] and the European Fund for Regional Development, 'A way to make Europe'

Aprender no es aburrido

Este proyecto pretende fomentar el interés de los alumnos por el aprendizaje y que adquieran los conceptos mínimos de las distintas materias que componen el currículo de ESO. A la vez, se trabajan las destrezas básicas y las técnicas de estudio a través de juegos. Cada grupo elabora un juego de mesa de preguntas y respuestas y diseñan ellos mismos el tablero y las reglas del juego. Estos juegos se intercambian entre los distintos grupos y se usan para repasar los contenidos de las asignaturas. Además se realiza un juego que consiste en tres pruebas individuales de conocimientos y dos pruebas colectivas de investigación que permiten a cada clase ir sumando puntos. La clase que queda primera gana una excursión. El proyecto ha recibido una gran acogida por parte del alumnado que se ha esforzado por trabajar en equipo, y también ha recibido una valoración muy positiva por parte del profesorado que considera que ha incidido positivamente en los resultados académicos de los alumnos. El proyecto adjunta tres CD-ROM con el juego de Historia del Arte de segundo de Bachillerato, Educación Física de primero de Bachillerato y de memoria visual; y un anexo con la lista de materiales elaborados y fotografías del desarrollo de la experiencia.Madrid (Comunidad Autónoma). Consejería de Educación. Dirección General de Ordenación AcadémicaMadridMadrid (Comunidad Autónoma). Subdirección General de Formación del Profesorado. CRIF Las Acacias; General Ricardos 179 - 28025 Madrid; Tel. + 34915250893ES

Resiliencia: espacios de adaptación de nuestras ciudades a los nuevos retos urbanos

La presente publicación recoge las reflexiones y experiencias desarrolladas en la Red de Investigación RE-ADAP “Resiliencia: espacios de adaptación de nuestras ciudades a los nuevos retos urbanos”(RED2018-102795-T Plan Estatal I+D+i 2017-2020), tanto por los investigadores e investigadoras que conforman la Red, y sus grupos de investigación, como por todas aquellas personas que han participado en los diferentes Seminarios, Boletines y Píldoras de Investigación realizados en el marco de la Red. El objetivo principal de la Red ha sido articular un enfoque conjunto, integral e innovador que afronte los retos de nuestras ciudades mediante la implantación de políticas públicas urbanas que incorporen la resiliencia. Esta publicación parte de una serie de aproximaciones teóricas a los ejes temáticos de la misma: Inclusión, Salud y Bienestar (ISB), Cambio Climático y Transición Ecológica (CCTE), Soberanía Alimentaria y Servicios Ecosistémicos (SASE) y Espacios de Adaptación (EA); que se complementa con un Catálogo de programas, proyectos de investigación e iniciativas públicas que se encuadran en los diferentes ejes temáticos, además de una Memoria de las actividades realizadas por la Red

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective